Prognostic factors for progression of early-and late-stage calcific aortic valve disease in Japanese: The Japanese Aortic Stenosis Study (JASS) Retrospective Analysis

Hypertension Research

Volumn 33, Issue 3, 2010, Pages 269-274

  Yamamoto, Kazuhiro ^a,b   Yamamoto, Hideya ^c   Yoshida, Kiyoshi ^d   Kisanuki, Akira ^e   Hirano, Yutaka ^f   Ohte, Nobuyuki ^g   Akasaka, Takashi ^h   Takeuchi, Masaaki ⁱ   Nakatani, Satoshi ^b   Ohtani, Tomohito ^b   Sozu, Takashi ^a   Masuyama, Tohru ^j  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f KINDAI UNIVERSITY HOSPITAL   (Japan)

^g NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^h WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^j HYOGO COLLEGE OF MEDICINE   (Japan)

more..

Author keywords

Angiotensin receptor blocker; Aortic valve; Calcification

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; WARFARIN;

ADULT; AGED; AORTA STENOSIS; AORTA VALVE DISEASE; AORTA VALVE REGURGITATION; ARTICLE; BLOOD VESSEL CALCIFICATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PROGNOSIS; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTICOAGULANTS; AORTIC VALVE STENOSIS; CALCINOSIS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WARFARIN;

EID: 77749246325     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.225     Document Type: Article

References (39)

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368: 1005-1011.
2. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24: 1231-1243.
3. Stewart B, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630-634.
4. Bahler RC, Desser DR, Finkelhor RS, Brener SJ, Youssefi M. Factors leading to progression of valvular aortic stenosis. Am J Cardiol 1999; 84: 1044-1048.
5. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N EnglJ Med 1999; 341: 142-147.
6. Novaro GM, Katz R, Aviles RJ, Gottdiener JS, Cushman M, Psaty BM, Otto CM, Griffin BP. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: The Cardiovascular Health Study. J Am Coll Cardiol 2007; 50: 1992-1999.
7. Ortlepp JR, Schmitz F, Mevissen V, Weifi S, Huster J, Dronskowski R, Langebartels G, Autschbach R, Zerres K, Weber C, Hanrath P, Hoffmann R. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 2004; 25: 514-522.
8. O'Brien KD. Pathogenesis of calcific aortic valve disease; a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006; 26: 1721-1728.
9. Goldbarg SH, Elmariah S, Miller MA, Fuster V. Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007; 50: 1205-1213.
10. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Peña-Silva R, Heistad DD. Dysregula-tion of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008; 52: 843-850.
11. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD, Miyake-Hull CY, Schwaegler RG. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95: 2262-2270.
12. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
13. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, Hori M, Lim YJ, Mishima M, Masuyama T. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 55-60.
14. Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Hori M, Yamamoto K. Difference of clinical characteristics between hypertensive patients with and without diastolic heart failure: role of diastolic dysfunction and renal insufficiency. Hypertens Res 2008; 31: 1865-1872.
15. Quinones MA, Waggoner AD, Reduto LA, Nelson JG, Young JB, Winters Jr WL, Ribeiro LG, Miller RR. A new simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 1981; 64: 744-753.
16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, St John Sutton M, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
17. Faggiano P, Antonini-Canterin F, Erlicher A, Romeo C, Cervesato E, Pavan D, Piazza R, Huang G, Nicolosi GL. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol 2003; 91: 99-101.
18. Cosmi JE, Kort S, Tunick PA, Rosenzweig BP, Freedberg RS, Katz ES, Applebaum RM, Kronzon I. The risk of the development of aortic stenosis in patients with benign aortic valve thickening. Arch Intern Med 2002; 162: 2345-2347.
19. Dichtl W, Alber HF, Feuchtner GM, Hintringer F, Reinthaler M, Bartel T, Süssenbacher A, Grander W, Ulmer H, Pachinger O, Müller S. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). Am J Cardiol 2008; 102: 743-748.
20. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343: 611-617.
21. O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, Probstfield JL. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002; 106: 2224-2230.
22. Helske S, Lindstedt KA, Laine M, Mäyränpää M, Werkkala K, Lommi J, Turto H, Kupari M, Kovanen PT. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004; 44: 1859-1866.
23. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T, Hanafusa T. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007; 49: 1482-1489.
24. Vermeer C. Gamma-carboxyglutamate-containing proteins and the vitamin K-depen-dent carboxylase. Biochem J 1990; 266: 625-636.
25. Koos R, Mahnken AH, Muhlenbruch G, Brandenburg V, Pflueger B, Wildberger JE, Kuhl HP. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005; 96: 747-749.
26. Schurgers LJ, Aebert H, Vermeer C, Bultmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 2004; 104: 3231-3232.
27. Jassal DS, Tam JW, Bhagirath KM, Gaboury I, Sochowski RA, Dumesnil JG, Giannoc-caro PJ, Jue J, Pandey AS, Joyner CD, Teo KK, Chan KL. Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. Eur Heart J 2008; 29: 1542-1547.
28. O'Meara E, Clayton T, McEntegart MB, McMurray JJV, Piña IL, Granger CB, stergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007; 115: 3111-3120.
29. Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, Dickstein K, Ponikowski P, Tavazzi L, Follath F, Lopez-Sendon JL. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail 2008; 10: 140-148.
30. Erbel R, Delaney JA, Lehmann N, McClelland RL, Möhlenkamp S, Kronmal RA, Schmermund A, Moebus S, Dragano N, Stang A, Jöckel KH, Budoff MJ. Signs of subclinical coronary atherosclerosis in relation to risk factor distribution in the MultiEthnic Study of Atherosclerosis (MESA) and the Heinz Nixdorf Recall Study (HNR). Eur Heart J 2008; 29: 2782-2791.
31. Nevaril CG, Lynch EC, Alfrey Jr CP, Hellums JD. Erythrocyte damage and destruction induced by shearing stress. J Lab Clin Med 1968; 71: 784-790.
32. MacCallum RN, Lynch EC, Hellums JD, Alfrey CP Jr. Fragility of abnormal erythrocytes evaluated by response to shear stress. J Lab Clin Med 1975; 85: 67-74.
33. Jacobson RJ, Rath CE, Perloff JK. Intravascular haemolysis and thrombocytopenia in left ventricular outflow obstruction. Br Heart J 1973; 35: 849-854.
34. Pareti FI, Lattuada A, Bressi C. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102: 1290-1295.
35. Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, Jude B. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-349.
36. Umana E, Ahmed W, Alpert MA. Valvular and perivalvular abnormalities in end-stage renal disease. Am J Med Sci 2003; 325: 237-242.
37. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, Rajamannan NM. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49: 554-561.
38. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-2397.
39. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjærpe T, Wachtell K, Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-1356.